SYNOPSIS: Wockhardt Limited reported a strong turnaround in Q2 FY26 with a net profit of Rs. 82 crores, 58 percent QoQ EBITDA growth, and robust biotech performance driven by emerging markets and strategic partnerships.
Shares of a research-based global pharmaceutical and biotech company surged nearly 12 percent on Monday, after reporting Q2 FY26 financial results, marking a strong financial turnaround with a net profit of Rs. 82 crores compared to losses in both the previous quarter and the same period last year.
With a market cap of Rs. 22,991 crores, shares of Wockhardt Limited closed in the green at Rs. 1,414.95 on BSE, up by around 10.4 percent, compared to its previous closing price of Rs. 1,281.3.
The stock has delivered positive returns of over 8 percent in one year, but has fallen by nearly 3 percent in the last one month.
What’s the News:
Wockhardt Limited announced the financial results for the second quarter of FY26 on Monday during market hours, as per the latest regulatory filings with the stock exchanges.
For Q2 FY26, the company posted a consolidated revenue from operations of Rs. 782 crores, reflecting a modest sequential rise of nearly 6 percent QoQ compared to Rs. 738 crores in Q1 FY26, but a year-on-year decline of around 3.3 percent from Rs. 809 crores recorded in Q2 FY25.
During the quarter, Wockhardt delivered a strong financial turnaround, reporting a net profit of Rs. 82 crore, compared to a net loss of Rs. 108 crore in the previous quarter and a net loss of Rs. 16 crore in the corresponding period last year.
Further, the company reported a strong 58 percent quarter-on-quarter growth in EBITDA, reaching Rs. 160 crore in Q2 FY26, compared to Rs. 101 crore in Q1 FY26.
The overall biotech operations for the quarter stood at Rs. 154 crore, reflecting a robust growth of 42 percent over Q4 FY25 and 41 percent over Q1 FY26. This performance was primarily supported by the emerging market biotech segment, which expanded by over 50 percent, fueled by accelerated business opportunities, strategic collaborations, and new deal acquisitions across key geographies such as Thailand, Egypt, Algeria, and Latin America. Additionally, the company’s domestic biotech business registered double-digit growth, highlighting consistent demand and a strong market position.
The company continues to strengthen its leadership in the biotech diabetes segment, backed by new partnerships across emerging markets and India and entry into new territories such as Russia and Malaysia. The upcoming launch of insulin analogues in the next few quarters is expected to further enhance its global presence and reinforce its position in diabetes care.
Regionally, the India business reported Rs. 172 crore in revenue in Q2 FY26, marking a 3 percent year-on-year growth. The UK business contributed Rs. 313 crore, up 4 percent YoY, while the Irish business delivered an exceptional 40 percent YoY growth, reaching Rs. 59 crore.
As per the September 2025 shareholding pattern, the ace investor Rekha Jhunjhunwala holds a 1.75 percent stake in the company.
Wockhardt Limited is a research-based global pharmaceutical and biotech company in the fields of pharmaceuticals, biotechnology and a chain of advanced super speciality hospitals. It has a significant presence in Europe and India, with 79 percent of its global revenues coming from international businesses.
The company is a global pharmaceutical and biotech company with presence in the UK, Switzerland, Ireland, Russia and many other countries. Wockhardt has manufacturing and research facilities in India & UK, and a manufacturing facility in Ireland and Dubai.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
